Innate Pharma S.A. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.71
Dividend & YieldN/A£ (N/A)
Beta 0.42
Market capitalization 1.94M
Operating cash flow -26.08M
ESG Scores unknown

Company description

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -51.67M -7.01M
Total Cashflows From Investing Activities 24.28M -62.12M -13.37M -917k
Net Borrowings -1.34M 11.92M -885k 26.63M
Total Cash From Financing Activities 61.22M 77.77M -1.18M 26.82M
Change To Operating Activities -47.1M 40.25M 25.38M -6.27M
Issuance Of Stock 62.67M 66.05M 48k 499k
Net Income 3.05M -20.76M -63.98M -52.81M
Change In Cash 52.95M 50.57M -66.1M -33.04M
Effect Of Exchange Rate -26k 5k 219k -483k
Total Cash From Operating Activities -32.53M 34.92M -51.77M -58.46M
Depreciation 7.34M 16.53M 13.27M 4.6M
Change To Account Receivables -22.92M -22.92M -22.92M 3.39M
Other Cashflows From Financing Activities -103k -203k -340k -312k
Change To Netincome 4.18M -1.09M 48.16M -360k
Capital Expenditures -873k -1.27M -907k -929k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax 2.72M 7.87M -829k -45.48M
Net Income 3.05M -20.76M -63.98M -52.81M
Selling General Administrative 18.14M 20.98M 18.99M 25.52M
Gross Profit 24.4M 22.55M 20.07M -22.3M
Ebit 5.15M 1.57M 1.08M -47.83M
Operating Income 5.15M 1.57M 1.08M -47.83M
Interest Expense -102k -204k -341k -312k
Income Tax Expense -333k
Total Revenue 93.95M 85.45M 69.77M 24.7M
Cost Of Revenue 69.56M 62.9M 49.71M 47M
Total Other Income ExpenseNet -2.43M 6.29M -1.91M 2.35M
Net Income From Continuing Ops 3.05M 7.87M -829k -45.48M
Net Income Applicable To Common Shares 3.05M -20.76M -63.98M -52.81M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 283.98M 183.94M 151.45M 160.06M
Total Stockholder Equity 167.24M 217.42M 155.98M 107.44M
Other Current Liabilities 166.81M 91.76M 22.61M 34.41M
Total Assets 451.22M 401.36M 307.42M 267.5M
Common Stock 3.2M 3.94M 3.95M 3.98M
Other Current Assets 1.26M 197k 1.11M 2.36M
Retained Earnings -134.79M -155.67M -220.46M -272.21M
Treasury Stock -1.1M -471k 355k 455k
Cash 152.31M 202.89M 136.79M 103.76M
Total Current Liabilities 196.74M 121.82M 45.49M 79.89M
Other Stockholder Equity -1.1M -471k 355k 455k
Property, Plant, and Equipment 10.22M 11.67M 11.69M 10.17M
Total Current Assets 319.64M 237.6M 173.45M 138.26M
Net Tangible Assets 82.71M 120.45M 109.69M 63.25M
Net Receivables 146.64M 13.14M 13.87M 13.47M
Accounts Payable 28.58M 27.94M 20.73M 14.73M


Insider Transactions

Here are the insider transactions of stock shares related to Innate Pharma S.A.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Innate Pharma S.A.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Innate Pharma S.A.

Here is the result of two systematic investment strategies applied to Innate Pharma S.A.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Innate Pharma S.A.

The following chart shows the equity curve of the two systematic investment strategies applied to Innate Pharma S.A.:

Innate Pharma S.A. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Innate Pharma S.A.

This is the result of two momentum investment strategies applied to Innate Pharma S.A.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Innate Pharma S.A.

The following chart shows all the entries opened by the momentum investment system on Innate Pharma S.A.:

Innate Pharma S.A. momentum entries
  • The first momentum investment strategy would give 0.0% of return on Innate Pharma S.A.. That represents 0.0£ of latent gain with 251.83£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Innate Pharma S.A.. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

0.0 %

Latent gain

0.0 £

Invested capital

251.83 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Innate Pharma S.A.

The following chart shows the equity curve of the two momentum strategies applied to Innate Pharma S.A.:

Innate Pharma S.A. momentum equity

Note: the dividends potentially given by Innate Pharma S.A. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Innate Pharma S.A.

The following chart shows the employed capital evolution of the two momentum strategies on Innate Pharma S.A. since the beginning:

Innate Pharma S.A.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Innate Pharma S.A.

Buy the dip entry openings on Innate Pharma S.A.

Innate Pharma S.A.

The performance achieved by the robo-advisor on Innate Pharma S.A. is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Innate Pharma S.A. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Innate Pharma S.A., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Innate Pharma S.A.

The following chart shows the result of the investment strategy applied to Innate Pharma S.A.:

Innate Pharma S.A.

Note: the dividends potentially given by Innate Pharma S.A. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Innate Pharma S.A.

The following chart shows the employed capital evolution since the beginning of the investment strategy on Innate Pharma S.A.:

Innate Pharma S.A.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Innate Pharma S.A.

In this section, I will compare the three previous investment strategies applied to Innate Pharma S.A..

Equity curve comparison on Innate Pharma S.A.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Innate Pharma S.A. investment strategy comparison

Employed capital comparison on Innate Pharma S.A.

Innate Pharma S.A. investment comparison

Performance comparison on Innate Pharma S.A.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 0.0% 0.0£ 251.83£ 0.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Innate Pharma S.A.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Innate Pharma S.A. and the other stocks. There may be false positives or some missing correlated stocks. If the price of Innate Pharma S.A. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Innate Pharma S.A.
Country France
City Marseille
Address 117, Avenue de Luminy
Phone 33 4 30 30 30 30
Website www.innate-pharma.com
FullTime employees 213
Industry
Sector
Exchange XLON
Ticker 0EVI.XLON
Market www.londonstockexchange.com

Innate Pharma S.A. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown